| Literature DB >> 35135841 |
Kelly M Jardon1,2, Emanuel E Canfora1, Gijs H Goossens1, Ellen E Blaak3,2.
Abstract
Accumulating evidence indicates that the gut microbiome is an important regulator of body weight, glucose and lipid metabolism, and inflammatory processes, and may thereby play a key role in the aetiology of obesity, insulin resistance and type 2 diabetes. Interindividual responsiveness to specific dietary interventions may be partially determined by differences in baseline gut microbiota composition and functionality between individuals with distinct metabolic phenotypes. However, the relationship between an individual's diet, gut microbiome and host metabolic phenotype is multidirectional and complex, yielding a challenge for practical implementation of targeted dietary guidelines. In this review, we discuss the latest research describing interactions between dietary composition, the gut microbiome and host metabolism. Furthermore, we describe how this knowledge can be integrated to develop precision-based nutritional strategies to improve bodyweight control and metabolic health in humans. Specifically, we will address that (1) insight in the role of the baseline gut microbial and metabolic phenotype in dietary intervention response may provide leads for precision-based nutritional strategies; that (2) the balance between carbohydrate and protein fermentation by the gut microbiota, as well as the site of fermentation in the colon, seems important determinants of host metabolism; and that (3) 'big data', including multiple omics and advanced modelling, are of undeniable importance in predicting (non-)response to dietary interventions. Clearly, detailed metabolic and microbial phenotyping in humans is necessary to better understand the link between diet, the gut microbiome and host metabolism, which is required to develop targeted dietary strategies and guidelines for different subgroups of the population. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: glucose metabolism; intestinal bacteria; nutrition; obesity
Mesh:
Year: 2022 PMID: 35135841 PMCID: PMC9120404 DOI: 10.1136/gutjnl-2020-323715
Source DB: PubMed Journal: Gut ISSN: 0017-5749 Impact factor: 31.793
Figure 1Interactions between diet and saccharolytic and proteolytic fermentation in the gut and host metabolism. Fermentation of dietary fibres occurs mainly in the proximal colon and yields SCFAs that can both be used as fuel for enterocytes and can act as peripheral signalling molecules. SCFAs are involved in centrally regulating food intake and energy expenditure by effects on secretion of GLP-1 and PYY. SCFAs are beneficial regulators of interorgan crosstalk between the gut and peripheral organs like the liver and muscle. Protein fermentation mainly occurs in the distal colon and yields a more diverse range of metabolites, including BCFAs, which are associated with detrimental effects on gut and metabolic health. Green boxes indicate effects of SCFAs on metabolic processes in peripheral organs. Blue borders indicate effects in the opposite direction site direction (dotted line) or unknown direction (no line) of proteolytic fermentation products. BCFA, branched-chain fatty acid; FA, fatty acid; GLP-1, glucagon-like peptide 1; PYY, peptide YY; SCFA, short-chain fatty acid; TMAO, trimethylamine N-oxide.
Effects of interventions with dietary fibre, carbohydrates and protein and changes in dietary patterns on gut microbiota and host metabolism in healthy, overweight, obese and insulin resistant individuals
| Diet | Study design | Functional outcomes | Gut microbiota composition and functionality | Individuals | Reference |
| Dietary protein | |||||
| High protein/moderate CHO (HPMC) and HP/low CHO (HPLC) | 28-day, randomised, cross-over design | HPMC and HPLC: increased faecal branched-chain fatty acids and concentrations of phenylacetic acid and N-nitroso compounds | HPMC: no significant changes | 17 men with obesity (BMI: 30.0–48.5 kg/m2) |
|
| LC/higher protein isocaloric | 14 weeks, parallel design | Liver fat ↓ | Rapid microbial alterations: | 10 adults with obesity/NAFLD |
|
| Dietary fibre and carbohydrates | |||||
| Barley kernel bread (37.6 g fibre/day) | 3 days, randomised cross-over design (vs white bread reference 9.1 g fibre/day) | Increased plasma GLP-1, PYY, breath H2 excretion, fasting serum SCFAs, improved insulin sensitivity index (p<0.05) | Increased | 39 healthy adults (BMI: 18–28 kg/m2) |
|
| 16 g oligofructose (8 g two times) per day | 2 weeks, placebo-controlled (16 g dextrin maltose), parallel design | Reduced 2-hour postprandial glucose AUC (p<0.05) Increased plasma GLP-1 and PYY levels and increased breath–hydrogen excretion | Not determined | 10 healthy adults (BMI mean±SD: 21.6±0.99 kg/m2) |
|
| 16 g FOS or GOS per day | 2 weeks, cross-over design | Increased fasting glucose |
| 35 healthy adults |
|
| RS versus NSP | 3 weeks, randomised cross-over design | Inverse relationship gut microbiota diversity–dietary responsiveness | ↑ Ruminococcaceae and ↑ Lachnospiraceae | 14 men with MetS (BMI: 27.9–51.3 kg/m2) |
|
| 30 g RS (10 g three times) per day | 4 weeks, placebo controlled (20 g digestible starch), two-way crossover | Improved whole-body insulin sensitivity (euglycaemic–hyperinsulinaemic clamp) (p<0.05). | Not determined | 10 healthy adults (BMI: 18.4–32.3 kg/m2 |
|
| 16 g inulin/oligofructose mix (8 g two times) per day | 12 weeks, parallel design, placebo controlled (16 g maltodextrin) | Reduced post-OGTT glucose response (7%, p<0.01); no effects on HOMA, fasting glucose and insulin and HbA1c | ↑ | 30 women with obesity (BMI, >30 kg/m2) |
|
| 15 g GOS (5 g, three times) per day | 12 weeks, placebo-controlled | No effects on glucose or insulin homeostasis, no increases in fasting SCFA plasma concentrations or faecal SCFAs | Fivefold increase in faecal | 44 adults with prediabetes andoverweight/obesity (BMI: 25–35 kg/m2) |
|
| 5.5 g GOS mixture 1×/day | 12 weeks, placebo-controlled | Decreased fasting insulin (p<0.01), triglyceride and C reactive protein plasma concentrations | Increased | 45 adults with overweight/obesity (BMI >25 kg/m2) |
|
| Dietary patterns | |||||
| Animal-based diet (very low fibre) versus plant-based diet (high fibre) | 5 days, cross-over design | Altered bile acid metabolism, plant polysaccharide fermentation ↓ |
| 10 healthy, lean and overweight adults (BMI: 19–32 kg/m2) |
|
| Mediterranean diet compared with energy-reduced Mediterranean diet and physical activity promotion | 1 year | BMI, fasting glucose, glycated haemoglobin and triglycerides ↓, |
| 400 adults with MetS |
|
AUC, area under the curve; BMI, body mass index; FOS, fructo-oligosaccharide; GLP-1, glucagon-like peptide 1; GOS, galacto-oligosaccharide; HOMA, homeostasis model assessment; HP, high protein; HPLC, high protein/low carbohydrate (CHO); HPMC, high protein/moderate carbohydrate (CHO); LC, low CHO; MetS, metabolic syndrome; NAFLD, non-alcoholic fatty liver disease; NSP, non-starch polysaccharide; OGTT, oral glucose tolerance test; PYY, peptide YY; RS, resistant starch; SCFA, short-chain fatty acid.
Figure 2Applying optimal strategies in precision nutrition requires detailed characterisation of the individual. The composition and functionality of the gut microbiota are influenced by many factors, including genetics, age, sex and environmental factors such as the mode of delivery, drug use, disease, geography, physical exercise and diet.19 The multidirectional interaction between the gut microbiota, host metabolism and diet is therefore complex and highly individualised. When developing more targeted dietary strategies for individuals A, B and C, the microbial and metabolic phenotypes (eg, tissue-specific insulin resistance), as well as characteristics of dietary components (including the balance between protein and carbohydrate (CHO)/fibre intake) should be well considered.